Solid Tumor Cancer Treatment Market – Size and Forecast 2021 | AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG
The global solid tumor cancer treatment market was valued at US$ 121.3 Bn in 2018, and is expected to reach US$ 424.6 Bn by 2027, expanding at a CAGR of 15.0% from 2019 to 2027.
Market Insights
As per the research findings of International Agency for Research (IARC) on Cancer in association with World Health Organization (WHO) in 2018, approximately 18.1 million new cases of cases were reported. They also claim that 1 in 6 women and 1 in 5 men are likely to develop cancer during their lifetime.
Breast cancer is dominating the indication segment for solid tumor cancer treatment market. The major factors hold responsible for its rising prevalence in female population worldwide is hormonal imbalance during the menstrual cycle, unhealthy lifestyle and low or no breastfeeding during lifetime. A significant spurt is expected to be seen in the prevalence rate of lung cancer throughout the globe on account of significant rise in the number of smokers and rising air pollution at an alarming rate.
Chemotherapy is currently the largest market in the therapy segment for solid tumor cancer treatment. Availability of its generic version at affordable cost increases its popularity in treating cancer. It is used alone or in combination for treating tumors in different parts of the human body. Biological molecules such as immunotherapy and targeted therapy are gaining prominence in cancer treatment on account of its excellent pharmacodynamic features ensuring minimal side effects and maximum therapeutic efficacy. Favorable reimbursement scenario further increases its demand in cancer treatment.
North America is presently holding 33.6% market share in the regional segment for solid tumor cancer treatment market. According to the research citing brought forward by Center for Disease Control and Prevention, in a span of 10 years form 2010-2020, in the United States approximately 1 million cases will be reported in men population and 900,000 in female population annually. Europe accounts for 30.2% market share on account of supportive regulatory environment provided by European Medical Agency (EMA) for the development and sale of medicines used in treatment of solid tumor cancer. Asia Pacific with a share of 19.5% is keen to register magnificent growth in the near future owing to the rising public health awareness regarding cancer and its treatment and developing healthcare infrastructure.
Pharmaceutical companies spearheading the solid tumor cancer treatment market are AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG, Bristol Myers Squibb & Company, Eli Lilly & Company, F.Hoffman La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc. and Olympus Medical Systems.
Key Market Movements:
- Significant rise in the diagnosis of new cases of cancer worldwide
- Recent approval of biologics exhibiting excellent pharmacodynamic properties with minimal side effects
- Affordable reimbursement scenario for medicines employed for the treatment of solid tumor cancer
Key questions answered in this report
- Which are the major biopharmaceutical companies actively providing medicines for the treatment of solid tumor cancer?
- Which organic and inorganic market growth strategies are being considered for performing market assessment?
- What is the disease etiology and prevalence rate of common types of cancer worldwide?
- What does biologics comprise of and what will be its CAGR during the growth period?
- What is the market size in developed regions such as North America and Europe?
Browse the full report Solid Tumor Cancer Treatment Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/solid-tumor-cancer-treatment-market
ToC:
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global STCT Market Portraiture
2.2. Global STCT Market, by Indication, 2018 (US$ Bn)
2.3. Global STCT Market, by Therapy, 2018 (US$ Bn)
2.4. Global STCT Market, by Geography, 2018 (US$ Bn)
Chapter 3. Solid Tumor Cancer Treatment (STCT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global STCT Market, by Key Players, 2018
Chapter 4. Global Solid Tumor Cancer Treatment (STCT) Market, by Indication
4.1. Overview
4.2. Breast Cancer
4.3. Cervical Cancer
4.4. Colorectal Cancer
4.5. Lung Cancer
4.6. Prostate Cancer
4.7. Others (Brain Tumor, Pancreatic Cancer etc.)
Chapter 5. Global Solid Tumor Cancer Treatment (STCT) Market, by Therapy
5.1. Chemotherapy
5.2. Targeted Therapy
5.3. Immunotherapy
5.4. Hormone Therapy
5.5. Surgical Procedures
Chapter 6. Global Solid Tumor Cancer Treatment (STCT) Market, by Geography
6.1. Overview
6.2. North America STCT Market Analysis, 2017– 2027
6.2.1. North America STCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.2.2. North America STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.2.3. North America STCT Market, by Country, 2017 – 2027 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe STCT Market Analysis, 2017 – 2027
6.3.1. Europe STCT Market, by Indication, 2017– 2027 (US$ Bn)
6.3.2. Europe STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.3.3. Europe STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific STCT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific STCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.4.2. Asia Pacific STCT Market, by Therapy, 2017– 2027 (US$ Bn)
6.4.3. Asia Pacific STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America STCT Market Analysis, 2017 – 2027
6.5.1. Latin America STCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.5.2. Latin America STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.5.3. Latin America STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa STCT Market Analysis, 2017 – 2027
6.6.1. MEA STCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.6.2. MEA STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.6.3. MEA STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA
Chapter 7. Company Profiles
7.1. AstraZeneca, Plc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Amgen, Inc.
7.3. B. Braun Melsungen AG
7.4. Bristol Myers Squibb & Company
7.5. Eli Lilly & Company
7.6. F.Hoffman La-Roche Ltd.
7.7. Merck & Co., Inc.
7.8. Novartis
7.9. Pfizer, Inc.
7.10. Olympus Medical Systems
Browse the full report Solid Tumor Cancer Treatment Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/solid-tumor-cancer-treatment-market
Related Reports:
Hypoallergenic Infant Formula For CMPA Market By Type (Extensively Hydrolyzed Formula, Amino Acid Based Elemental Formula, Soy-Based Formula, Rice-Based Formula, Other Milk Sources), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)- Growth, Share, Opportunities & Competitive Analysis, 2020 -2027
Media Contact
Company Name: Credence Research
Contact Person: Chris Smith
Email: Send Email
Phone: 18003618290
City: SAN JOSE
State: CA
Country: United States
Website: https://www.credenceresearch.com/report/solid-tumor-cancer-treatment-market
